<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30191351</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Print">2191-219X</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>8</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>06</Day>                    </PubDate>                </JournalIssue>                <Title>EJNMMI research</Title>                <ISOAbbreviation>EJNMMI Res</ISOAbbreviation>            </Journal>            <ArticleTitle>PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma.</ArticleTitle>            <Pagination>                <MedlinePgn>90</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13550-018-0442-0</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">CXCR4 is a chemokine receptor frequently overexpressed in invasive breast cancer that has been shown to play a major role in signaling pathways involved in metastasis. The aim of this retrospective analysis was to assess the diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer using the recently introduced CXCR4-targeted PET probe <sup>68</sup>Ga-Pentixafor.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirteen patients with first diagnosis of breast cancer, four patients with recurrent disease after primary breast cancer, and one patient with axillary lymph node metastasis of unknown primary underwent CXCR4-targeted PET imaging using <sup>68</sup>Ga-Pentixafor. Maximum standardized uptake values (SUVmax) and tumor-to-background (T/B) ratios of tumor lesions were measured and compared with pathological prognostic factors and molecular subtypes. <sup>18</sup>F-FDG PET/CT images were available in 8/18 cases and were compared semi-quantitatively. Comparison with CXCR4 expression determined by immunohistochemistry was performed in 7/18 patients. Nine of 13 primary breast cancers were visually detectable on <sup>68</sup>Ga-Pentixafor PET images (mean SUVmax of 3.0). The visually undetectable lesions included both cases of invasive lobular carcinoma (ILC) and two cases of invasive carcinoma of no special type (NST) without any hormone receptor and HER2 expression (triple negative). Metastases of recurrent breast cancer and unknown primary cancer were visually detectable in all five cases, exhibiting a mean SUVmax of 3.5. <sup>18</sup>F-FDG PET demonstrated higher SUVmax in all patients compared to <sup>68</sup>Ga-Pentixafor PET. A correlation between SUVmax obtained from <sup>68</sup>Ga-Pentixafor PET and prognostic factors including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) status, proliferation index, tumor grade, or molecular subtypes was not observed.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">CXCR4-directed PET imaging in patients with primary and recurrent breast cancer is feasible; however, tumor detectability is significantly lower compared to <sup>18</sup>F-FDG PET. Moreover, we did not find any correlation between aforementioned prognostic factors of breast cancer and CXCR4-targeted tracer accumulation. Based on these results in a small patient cohort, CXCR4-targeted PET imaging does not seem to be suitable as a general diagnostic tool for imaging of breast cancer. Future CXCR4 imaging studies should investigate whether this modality might be useful in more specific applications, e.g., in therapeutic approaches especially under the view of current developments in targeted immune cell and immune checkpoint inhibitory therapy.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Vag</LastName>                    <ForeName>Tibor</ForeName>                    <Initials>T</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-9004-7683</Identifier>                    <AffiliationInfo>                        <Affiliation>Clinic of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Ismaninger Strasse 22, 81675, Munich, Germany. tibor.vag@tum.de.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Steiger</LastName>                    <ForeName>Katja</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Institute of Pathology, Technische Universität München, Troger Strasse 18, 81675, Munich, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rossmann</LastName>                    <ForeName>Andreas</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Clinic of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Keller</LastName>                    <ForeName>Ulrich</ForeName>                    <Initials>U</Initials>                    <AffiliationInfo>                        <Affiliation>III Medical Department, Klinikum Rechts der Isar, Technische Universität München, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Noske</LastName>                    <ForeName>Aurelia</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Institute of Pathology, Technische Universität München, Troger Strasse 18, 81675, Munich, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Herhaus</LastName>                    <ForeName>Peter</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>III Medical Department, Klinikum Rechts der Isar, Technische Universität München, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ettl</LastName>                    <ForeName>Johannes</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Clinic of Gynecology, Klinikum Rechts der Isar, Technische Universität München, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Niemeyer</LastName>                    <ForeName>Markus</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Clinic of Gynecology, Klinikum Rechts der Isar, Technische Universität München, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wester</LastName>                    <ForeName>Hans-Jürgen</ForeName>                    <Initials>HJ</Initials>                    <AffiliationInfo>                        <Affiliation>Pharmaceutical Radiochemistry, Technische Universität München, Walther-Meissner Strasse 3, 85748, Garching, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Schwaiger</LastName>                    <ForeName>Markus</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Clinic of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>SFB 824</GrantID>                    <Agency>Deutsche Forschungsgemeinschaft</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>06</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Germany</Country>            <MedlineTA>EJNMMI Res</MedlineTA>            <NlmUniqueID>101560946</NlmUniqueID>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2004 Dec 1;64(23):8604-12</RefSource>                <PMID Version="1">15574767</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2015 Aug;26(8):1533-46</RefSource>                <PMID Version="1">25939896</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Pathol. 2007 Mar;60(3):261-6</RefSource>                <PMID Version="1">16751302</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Anal Cell Pathol (Amst). 2015;2015:289510</RefSource>                <PMID Version="1">26576337</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Theranostics. 2015 Mar 01;5(6):618-30</RefSource>                <PMID Version="1">25825601</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2016 Feb 23;7(8):9288-95</RefSource>                <PMID Version="1">26843617</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Biol Chem. 1999 Oct 22;274(43):31076-86</RefSource>                <PMID Version="1">10521508</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 2006 Nov 1;119(9):2026-9</RefSource>                <PMID Version="1">16671092</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2011 Jan 15;71(2):603-13</RefSource>                <PMID Version="1">21123450</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ultrastruct Pathol. 2012 Dec;36(6):381-6</RefSource>                <PMID Version="1">23216236</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2011 Nov 16;103(22):1656-64</RefSource>                <PMID Version="1">21960707</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>EMBO Mol Med. 2015 Mar 03;7(4):477-87</RefSource>                <PMID Version="1">25736399</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2001 Mar 1;410(6824):50-6</RefSource>                <PMID Version="1">11242036</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Nucl Med. 2016 May;57(5):741-6</RefSource>                <PMID Version="1">26769866</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Radiol. 2017 Apr;72(4):295-301</RefSource>                <PMID Version="1">28139203</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Theranostics. 2016 Jan 25;6(3):428-34</RefSource>                <PMID Version="1">26909116</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Blood. 2005 Sep 15;106(6):1901-10</RefSource>                <PMID Version="1">15890683</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Anal Cell Pathol (Amst). 2015;2015:891020</RefSource>                <PMID Version="1">26161302</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Cancer. 2014 Jan 29;14:49</RefSource>                <PMID Version="1">24475985</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncogene. 2016 Feb 18;35(7):816-26</RefSource>                <PMID Version="1">25961926</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Mol Med. 2013 Mar;13(3):410-6</RefSource>                <PMID Version="1">23331013</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast J. 2008 May-Jun;14(3):268-74</RefSource>                <PMID Version="1">18373506</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Nucl Med. 2011 Nov;52(11):1803-10</RefSource>                <PMID Version="1">22045709</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Immunol. 2017 Sep;17(9):559-572</RefSource>                <PMID Version="1">28555670</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Exp Med. 2003 Nov 3;198(9):1391-402</RefSource>                <PMID Version="1">14597738</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2010 Jun 1;16(11):2927-31</RefSource>                <PMID Version="1">20484021</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Tumour Biol. 2014 Feb;35(2):1581-8</RefSource>                <PMID Version="1">24101191</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Med Chem. 2011 Nov 10;54(21):7648-62</RefSource>                <PMID Version="1">21905730</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Nucl Med. 2012 Jun;53(6):845-55</RefSource>                <PMID Version="1">22534830</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Mol Med. 2014 Jan;14(1):174-84</RefSource>                <PMID Version="1">24256053</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30</RefSource>                <PMID Version="1">26742998</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Cell. 2004 Nov;6(5):459-69</RefSource>                <PMID Version="1">15542430</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Invest Radiol. 2015 Aug;50(8):505-13</RefSource>                <PMID Version="1">26115367</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur Radiol. 2017 Aug;27(8):3190-3198</RefSource>                <PMID Version="1">28004161</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Theranostics. 2013;3(1):76-84</RefSource>                <PMID Version="1">23382787</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Labelled Comp Radiopharm. 2013 Nov;56(13):679-85</RefSource>                <PMID Version="1">25196030</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">CXCR4</Keyword>            <Keyword MajorTopicYN="N">Chemokine receptor</Keyword>            <Keyword MajorTopicYN="N">Positron emission tomography</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>07</Month>                <Day>01</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>19</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>8</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>8</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>8</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30191351</ArticleId>            <ArticleId IdType="doi">10.1186/s13550-018-0442-0</ArticleId>            <ArticleId IdType="pii">10.1186/s13550-018-0442-0</ArticleId>            <ArticleId IdType="pmc">PMC6127070</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>